KYMERA THERAPEUTICS, INC. (KYMR) FY2026 Q3 Balance Sheet

Published Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

As of 2026-09-30

Balance Sheet

Swipe to see the full flow
KYMERA THERAPEUTICS, INC. (KYMR) FY2026 Q3 Balance SheetBalance sheet as of 2026-09-30. The chart shows assets, liabilities and equity at that date.Current liabilities$89.72 MCurrent assets$998.59 MLiabilities$152.74 MNon-current liabilities$63.02 MAssets$1.77 BEquity$1.61 BNon-current assets$768.68 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSMarketable securities (Note 4)Cash and cash equivalentsPrepaid expenses and other current assetsMarketable securities, non-current (Note 4)Right-of-use assets, operating leasesProperty and equipment, net (Note 6)Other non-current assetsRestricted cashAccrued expenses (Note 8)Operating lease liabilitiesAccounts payableFinance lease liabilitiesOther current liabilitiesOperating lease liabilities, net of current portionFinance lease liabilities, net of current portionAdditional paid-in capitalCommon stock, $0.0001 par value; 150,000,000 shares authorized at September 30, 2026 and December 31, 2025, 85,325,503 and 81,323,532 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectivelyAccumulated deficitAccumulated other comprehensive (loss) incomeCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityEquityAccrued expenses (Note 8)Accrued expenses (Note 8)$63.32 MOperating lease liabilitiesOperating lease liabilities$12.21 MCurrent liabilitiesCurrent liabilities$89.72 MAccounts payableAccounts payable$11.92 MCurrent assetsCurrent assets$998.59 MFinance lease liabilitiesFinance lease liabilities$1.37 MMarketable securities (Note 4)Marketable securities (Note 4)$597.84 MLiabilitiesLiabilities$152.74 MOther current liabilitiesOther current liabilities$905.00 KCash and cash equivalentsCash and cash equivalents$373.37 MNon-current liabilitiesNon-current liabilities$63.02 MOperating lease liabilities, net of current portionOperating lease liabilities, net of current portion$62.42 MPrepaid expenses and other current assetsPrepaid expenses and other current assets$27.38 MAssetsAssets$1.77 BFinance lease liabilities, net of current portionFinance lease liabilities, net of current portion$602.00 KMarketable securities, non-current (Note 4)Marketable securities, non-current (Note 4)$674.67 MEquityEquity$1.61 BNon-current assetsNon-current assets$768.68 MRight-of-use assets, operating leasesRight-of-use assets, operating leases$40.44 MAdditional paid-in capitalAdditional paid-in capital$2.96 BProperty and equipment, net (Note 6)Property and equipment, net (Note 6)$38.24 MOther non-current assetsOther non-current assets$9.11 MCommon stock, $0.0001 par value; 150,000,000 shares authorized at September 30, 2026 and December 31, 2025, 85,325,503 and 81,323,532 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectivelyCommon stock$9.00 KRestricted cashRestricted cash$6.21 MAccumulated deficitAccumulated deficit−$1.33 BAccumulated other comprehensive (loss) incomeOther comprehensive loss−$14.74 M
Chart details

KYMERA THERAPEUTICS, INC. (KYMR) FY2026 Q3 Balance Sheet

Balance sheet as of 2026-09-30. The chart shows assets, liabilities and equity at that date.

Assets
1,767,269,000 US dollars
Current assets
998,592,000 US dollars
Non-current assets
768,677,000 US dollars
Liabilities
152,742,000 US dollars
Current liabilities
89,723,000 US dollars
Non-current liabilities
63,019,000 US dollars
Equity
1,614,527,000 US dollars
Marketable securities (Note 4)
597,840,000 US dollars
Cash and cash equivalents
373,374,000 US dollars
Prepaid expenses and other current assets
27,378,000 US dollars
Marketable securities, non-current (Note 4)
674,669,000 US dollars
Right-of-use assets, operating leases
40,444,000 US dollars
Property and equipment, net (Note 6)
38,242,000 US dollars
Other non-current assets
9,113,000 US dollars
Restricted cash
6,209,000 US dollars
Accrued expenses (Note 8)
63,315,000 US dollars
Operating lease liabilities
12,209,000 US dollars
Accounts payable
11,923,000 US dollars
Finance lease liabilities
1,371,000 US dollars
Other current liabilities
905,000 US dollars
Deferred revenue
0 US dollars
Operating lease liabilities, net of current portion
62,417,000 US dollars
Finance lease liabilities, net of current portion
602,000 US dollars
Deferred revenue, net of current portion
0 US dollars
Additional paid-in capital
2,957,658,000 US dollars
Common stock, $0.0001 par value; 150,000,000 shares authorized at September 30, 2026 and December 31, 2025, 85,325,503 and 81,323,532 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively
9,000 US dollars
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 0 shares issued and outstanding as of September 30, 2026 and December 31, 2025
0 US dollars
Accumulated deficit
negative 1,328,405,000 US dollars
Accumulated other comprehensive (loss) income
negative 14,735,000 US dollars

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
KYMERA THERAPEUTICS, INC. (KYMR) FY2026 Q3 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!